أعلان
تحميل كتاب Tumor Necrosis Factor Methods and Protocols pdf
المؤلف : Angelo Corti Pietro Ghezzi
عن الكتاب : 2004م - 1443هـ
نبذه عن الكتاب:
1. History of TNF
1.1. The Era of Soluble Mediators and the Magic Bullets
Against Cancer
The 1970s and 1980s were the golden age of cytokines, during which the
biochemical nature of several soluble mediators was clarified. Cellular immunologists then identified macrophage-derived mediators that activate lymphocytes (lymphocyte-activating factors, or LAFs), along with lymphocyte-derived
mediators that activate macrophages (macrophage-activating factors, or
MAFs). These molecules added to the list of mediators defined as growth factors, which include hematopoietic growth factors (that now retain those names:
G-CSF, GM-CSF, EPO), and interferons (described as antiviral factors in the
late 1950s). One particularly active field was the research of soluble mediators
that could kill tumor cells or boost anticancer defenses. Along this line, earlier
studies focused on a lymphocyte-derived cytotoxin termed lymphotoxin (LT),
and research led to the discovery of a serum factor capable of inducing hemor-
2 Ghezzi and Cerami
rhagic necrosis of tumors in vivo and of killing tumor cells in vitro. This factor
was termed tumor necrosis factor (TNF) and was shown to be mainly a macrophage product, as opposed to LT. In 1985 several groups reported the cloning of human and mouse TNF and the ability of recombinant TNF to induce
hemorrhagic necrosis of tumors in mice. It would not have been easy, 15 years
ago, to predict that the main clinical application of the discovery and characterization of TNF would consist of the administration of anti-TNF molecules for
the therapy of rheumatoid arthritis and Crohn’s disease. In fact, TNF turned
out to be a key pathogenic mediator with pleiotropic activities, and its history
and path, from immunity to inflammation, was very similar to that of
interleukin (IL)-1. The fact that the characterization of the inflammatory action
of TNF stemmed from studies on models of sepsis was also unexpected.
1.2. From Cancer and Immunity to Endotoxic Shock and Septic Shock
Studies on the molecular basis of cachexia associated with sepsis led to the
finding that macrophages activated with endotoxin and used to reproduce settings of septic shock, release a factor that is cachectogenic in vivo and inhibits
ipogenesis in cultured adipocytes. We termed this factor “cachectin,” and then
we purified it, we found that it was identical to TNF.
These earlier studies pointed out a pathogenic role for TNF in sepsis and
inflammation, which was confirmed by earlier clinical trials with rTNF in
cancer patients showing toxicity in phase I and II studies. The first studies of
neutralization of endogenous TNF have shown that this cytokine is a lethal
mediator associated with toxicity of endotoxin (1) and septic shock induced by
live bacteria (2). These studies have pointed at the possible use of anti-TNF
antibodies in the therapy of septic shock. However, the clinical trials conducted
so far have not indicated a clear efficacy of anti-TNF in septic shock.
Indeed, after a period of great enthusiasm, during which septic shock was
considered the prototypic cytokine-mediated disease, most of the big pharmaceutical companies became daunted by the complexity of this pathological condition, which is associated with other diseases such as cancer, trauma, or burn
injury. Some attempts have been toward a narrower definition of the component of septic shock, including acute respiratory distress syndrome (ARDS)
and multiple organ failure (MOF), in which cytokines play an important role.
In 1992 the American College of Chest Physicians and the Society of Critical
Care Medicine Consensus Conference introduced the term “systemic inflammatory response syndrome” (SIRS) (3). Despite these difficulties, the scientists working in the field of cytokines and inflammation have continued using
the models of lipopolysaccharide (LPS) toxicity as a means of inducing a
systemic inflammatory response (to stick to the above definition). .
أعلان
الملكية الفكرية محفوظة لمؤلف الكتاب المذكور فى حالة وجود مشكلة بالكتاب الرجاء الإبلاغ من خلال الايميل الخاص بنا فى صفحة حقوق النشر أو من خلال صفحتنا على الفيس بوك.
وصف كتاب Tumor Necrosis Factor Methods and Protocols
2004م - 1443هـ
نبذه عن الكتاب:
1. History of TNF
1.1. The Era of Soluble Mediators and the Magic Bullets
Against Cancer
The 1970s and 1980s were the golden age of cytokines, during which the
biochemical nature of several soluble mediators was clarified. Cellular immunologists then identified macrophage-derived mediators that activate lymphocytes (lymphocyte-activating factors, or LAFs), along with lymphocyte-derived
mediators that activate macrophages (macrophage-activating factors, or
MAFs). These molecules added to the list of mediators defined as growth factors, which include hematopoietic growth factors (that now retain those names:
G-CSF, GM-CSF, EPO), and interferons (described as antiviral factors in the
late 1950s). One particularly active field was the research of soluble mediators
that could kill tumor cells or boost anticancer defenses. Along this line, earlier
studies focused on a lymphocyte-derived cytotoxin termed lymphotoxin (LT),
and research led to the discovery of a serum factor capable of inducing hemor-
2 Ghezzi and Cerami
rhagic necrosis of tumors in vivo and of killing tumor cells in vitro. This factor
was termed tumor necrosis factor (TNF) and was shown to be mainly a macrophage product, as opposed to LT. In 1985 several groups reported the cloning of human and mouse TNF and the ability of recombinant TNF to induce
hemorrhagic necrosis of tumors in mice. It would not have been easy, 15 years
ago, to predict that the main clinical application of the discovery and characterization of TNF would consist of the administration of anti-TNF molecules for
the therapy of rheumatoid arthritis and Crohn’s disease. In fact, TNF turned
out to be a key pathogenic mediator with pleiotropic activities, and its history
and path, from immunity to inflammation, was very similar to that of
interleukin (IL)-1. The fact that the characterization of the inflammatory action
of TNF stemmed from studies on models of sepsis was also unexpected.
1.2. From Cancer and Immunity to Endotoxic Shock and Septic Shock
Studies on the molecular basis of cachexia associated with sepsis led to the
finding that macrophages activated with endotoxin and used to reproduce settings of septic shock, release a factor that is cachectogenic in vivo and inhibits
ipogenesis in cultured adipocytes. We termed this factor “cachectin,” and then
we purified it, we found that it was identical to TNF.
These earlier studies pointed out a pathogenic role for TNF in sepsis and
inflammation, which was confirmed by earlier clinical trials with rTNF in
cancer patients showing toxicity in phase I and II studies. The first studies of
neutralization of endogenous TNF have shown that this cytokine is a lethal
mediator associated with toxicity of endotoxin (1) and septic shock induced by
live bacteria (2). These studies have pointed at the possible use of anti-TNF
antibodies in the therapy of septic shock. However, the clinical trials conducted
so far have not indicated a clear efficacy of anti-TNF in septic shock.
Indeed, after a period of great enthusiasm, during which septic shock was
considered the prototypic cytokine-mediated disease, most of the big pharmaceutical companies became daunted by the complexity of this pathological condition, which is associated with other diseases such as cancer, trauma, or burn
injury. Some attempts have been toward a narrower definition of the component of septic shock, including acute respiratory distress syndrome (ARDS)
and multiple organ failure (MOF), in which cytokines play an important role.
In 1992 the American College of Chest Physicians and the Society of Critical
Care Medicine Consensus Conference introduced the term “systemic inflammatory response syndrome” (SIRS) (3). Despite these difficulties, the scientists working in the field of cytokines and inflammation have continued using
the models of lipopolysaccharide (LPS) toxicity as a means of inducing a
systemic inflammatory response (to stick to the above definition). .
أعلان
أعلان
تحميل
| التحميل | حجم الكتاب |
|---|---|
| غير محدد فى الوقت الحالى |
أعلان
أضافة مراجعة
1 (0)
2 (0)
3 (0)
4 (0)
5 (0)
كتب ذات صلة بكتاب Tumor Necrosis Factor Methods and Protocols
0.0
كتاب Mineral and Thermal Waters of Southea ..
Petar Papić
كتب منوعة - Biology Books - غير محدد عدد الصفحات
0.0
كتاب Plant life and plant uses an elementa ..
غير معروف
كتب منوعة - Biology Books - غير محدد عدد الصفحات
0.0
كتاب Springer International Publishing
Colby Sawyer College Harvey
كتب منوعة - Biology Books - غير محدد عدد الصفحات
0.0
كتاب Parasitology or Mycology Lecture Guid ..
غير معروف
كتب منوعة - Biology Books - غير محدد عدد الصفحات